Universiteit Gent

Vib Vzw

Centre National De La Recherche Scientifique

Centre Hospitalier Régional Universitaire De Montpellier

Universitè De Montpellier

Universite Montpellier 2

Orionis Biosciences Bv

Frank Peelman

Jan Tavernier

Gilles Uze

Jennyfer Bultinck

Nikolai Kley

Lennart Zabeau

Rudi Beyaert

Sarah Gerlo

Gilles Uzé

Savvas Savvides

Kenneth Verstraete

Harald Braun

The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains can-y one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.

Targeted modified TNF family members

The present invention relates, in part, to chimeric proteins comprising mutant interferon-&#x3b2; and their use as therapeutic agents.

Targeted mutant interferon-beta and uses thereof

The present invention relates, in part, to chimeric proteins comprising mutant interferon-&#x3b3; and their use as therapeutic agents.

Targeted mutant interferon-gamma and uses thereof

The present invention relates to monomeric fusion proteins comprising the extracellular part of the thymic stromal lymphopoietin receptor (TSLPR) and the extracellular part of the interleukin-7 receptor alpha (IL-7Ralpha) as inhibitors of thymic stromal lymphopoietin (TSLP) activity. The invention relates further to the use of said inhibitors as a medicament in the treatment of&#x2014;but not limited to&#x2014;inflammatory diseases, cancer and fibrosis.

TSLP inhibitors

The present invention relates to a modified cytokine of the TNF superfamily, with reduced activity to its receptor, wherein said modified cytokine is specifically delivered to target cells. Preferably, said modified cytokine is a single chain variant of the TNF superfamily, even more preferably, one or more of the chains carry one or more mutations, resulting in a low affinity to the receptor, wherein said mutant cytokine is specifically delivered to target cells. The targeting is realized by fusion of the modified cytokine of the TNF superfamily to a targeting moiety, preferably an antibody or antibody-like molecule. The invention relates further to the use of such targeted modified cytokine of the TNF superfamily to treat diseases.

The present disclosure relates to a modified Interleukin-1 (IL-1) family member cytokine, with reduced activity via its cytokine receptor, wherein said interleukin-1 family member cytokine is specifically delivered to target cells. Preferably, the IL-1 family member cytokine is a mutant, more preferably it is a mutant IL-1 with low affinity to the IL-1 receptor, wherein said mutant IL-1 is specifically delivered to target cells. The targeting is preferably realized by fusion of the modified IL-1 family member cytokine to a targeting moiety, preferably an antibody or antibody-like molecule. The disclosure relates further to the use of such targeted modified IL-1 family member cytokine to treat diseases.

Targeted modified IL-1 family members

The present invention relates to an antagonist or inhibitor of leptin signaling via the leptin receptor. The leptin antagonist binds to the leptin receptor, but is unable to induce JAK-STAT signal transduction via the leptin receptor. By binding to the leptin receptor, the leptin antagonist impairs binding of leptin to the leptin receptor and blocks leptin signaling.

Growing community of inventors

Gentbrugge, Belgium

Frank Peelman